Te AE - Search Results

1

Metabolic syndrome and sexual dysfunction.

Chughtai B, Lee RK, Te AE, Kaplan SA. Chughtai B, et al. Among authors: te ae. Curr Opin Urol. 2011 Nov;21(6):514-8. doi: 10.1097/MOU.0b013e32834b8681. Curr Opin Urol. 2011. PMID: 21897258 Review.

2

Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?

Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, Kaplan SA. Choi J, et al. Among authors: te ae. Eur Urol. 2002 Jul;42(1):7-11. doi: 10.1016/s0302-2838(02)00222-1. Eur Urol. 2002. PMID: 12121722

3

PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.

Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. Kaplan SA, et al. Among authors: te ae. Urology. 2002 Sep;60(3):464-8. doi: 10.1016/s0090-4295(02)01760-0. Urology. 2002. PMID: 12350485 Clinical Trial.

4

A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome.

Kaplan SA, Volpe MA, Te AE. Kaplan SA, et al. Among authors: te ae. J Urol. 2004 Jan;171(1):284-8. doi: 10.1097/01.ju.0000101487.83730.80. J Urol. 2004. PMID: 14665895 Clinical Trial.

5

High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates.

Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. Sandhu JS, et al. Among authors: te ae. Urology. 2004 Dec;64(6):1155-9. doi: 10.1016/j.urology.2004.07.018. Urology. 2004. PMID: 15596189 Clinical Trial.

6

Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome.

Yang J, Te AE. Yang J, et al. Among authors: te ae. Curr Urol Rep. 2005 Jul;6(4):290-5. doi: 10.1007/s11934-005-0026-1. Curr Urol Rep. 2005. PMID: 15978232 Review.

7

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Kaplan SA, Walmsley K, Te AE. Kaplan SA, et al. Among authors: te ae. J Urol. 2005 Dec;174(6):2273-5. discussion 2275-6. doi: 10.1097/01.ju.0000181823.33224.a0. J Urol. 2005. PMID: 16280803

8

Photoselective laser vaporization prostatectomy in men receiving anticoagulants.

Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE. Sandhu JS, et al. Among authors: te ae. J Endourol. 2005 Dec;19(10):1196-8. doi: 10.1089/end.2005.19.1196. J Endourol. 2005. PMID: 16359214

9

The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia.

Lee R, Gonzalez RR, Te AE. Lee R, et al. Among authors: te ae. World J Urol. 2006 Sep;24(4):405-9. doi: 10.1007/s00345-006-0094-y. Epub 2006 May 13. World J Urol. 2006. PMID: 16699795 Review. No abstract available.

10

Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention.

Monoski MA, Gonzalez RR, Sandhu JS, Reddy B, Te AE. Monoski MA, et al. Among authors: te ae. Urology. 2006 Aug;68(2):312-7. doi: 10.1016/j.urology.2006.02.020. Urology. 2006. PMID: 16904443

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters